Evidence map›Paper›PMID 41236271›Full record

ArticleDermatology practical & conceptual2025

Elective First-Line Use of Dimethyl Fumarate in Psoriasis: Insights from an Italian Cohort.

Alessandro Giunta, Maria Esposito, Elena Campione, Martina Burlando, Giacomo Caldarola, Viviana Lora, Federico Diotallevi, Ersilia Tolino, Gianmarco Silvi, Emanuele Cozzani and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alessandro GiuntaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Maria EspositoDepartment of biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Elena CampioneDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Martina BurlandoClinica Dermatologica, DISSAL, Università di Genova, Genova, Italy.
Giacomo CaldarolaUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Viviana LoraDivision of Dermatology, San Gallicano Dermatological Institute, Rome, Italy.
Federico DiotalleviDermatological Clinic, Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy.
Ersilia TolinoUnit of Dermatology, Department of Medical-Surgical Science and Biotechnologies, Sapienza University of Rome, A. Fiorini Hospital, Terracina, Latina, Italy.
Gianmarco SilviSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
Emanuele CozzaniClinica Dermatologica, DISSAL, Università di Genova, Genova, Italy.
Ruslana Gaeta ShumakDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Rosaria FidanzaUOSD Dermatologia Generale ed Oncologica Ospedale San Salvatore L'Aquila ASL1 Abruzzo, L'Aquila, Italy.
Paolo AntonettiUOSD Dermatologia Generale ed Oncologica Ospedale San Salvatore L'Aquila ASL1 Abruzzo, L'Aquila, Italy.
Lorenzo Maria PintoUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Valentina MirisolaPolistudium Srl, Milan, Italy.
Maria Concetta FargnoliDepartment of biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Luca BianchiDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Francesca PrignanoSection of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDimethyl fumarate (DMF) is an approved conventional systemic treatment for psoriasis that does not exhibit any drug-drug interactions or cumulative organ toxicities.

aimThis retrospective real-world study aimed to analyze the long-term efficacy, safety, and tolerability of DMF in patients with moderate psoriasis.

methodsData on safety and efficacy were collected from medical charts. The effect on disease severity was assessed using the Psoriasis Area Severity Index.

resultsOur study included 148 patients over a 48-week treatment period, confirming DMF as an effective option in the treatment of moderate psoriasis. Adverse events were only mild or moderate, principally flushing, epigastralgia, and diarrhea. However, DMF exhibited a delayed onset of action, and the dropout rate was high. These aspects highlight the importance of educating patients about the activity profile of DMF, the potential occurrence of side effects, and their management. However, side effects are self-limiting with discontinuation of treatment and generally occur early, allowing patients to be promptly switched to other therapies if DMF is not tolerated.

conclusionsOur results confirm that DMF may be offered as a first-line treatment for moderate psoriasis as it demonstrated efficacy even in the long-term, when treatment is tolerated, especially in patients with a disease duration of less than five years. DMF may also be proposed when the patient presents comorbidities, when immunosuppression is undesired, and/or before the initiation of biological therapies.

Identifiers

PMID41236271
PMCPMC12615070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.